Apotex announces expansion of licensing agreement with Formosa Pharmaceuticals to Mexico for commercialization of clobetasol propionate ophthalmic suspension for the treatment of inflammation and pain
MEXICO CITY, May 6, 2025 /CNW/ - Apotex Inc. (referred to as "Apotex" or "the Company") today announced it has entered into an exclusive licensing agreement with Formosa Pharmaceuticals ("Formosa", 6838.TW), for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery, upon regulatory approval.
Apotex Inc. Logo (CNW Group/Apotex Inc.)
APP13007 was approved by the U.S. Food and Drug Administration (FDA) in 2024. APP13007's active ingredient is the corticosteroid clobetasol propionate, and it is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. This novel formulation proved statistically and clinically superior to its matching placebo in Phase 3 trials in the United States (p<0.001).
This license agreement for the Mexican market adds to Apotex's existing exclusive rights to this product in Canada.
"At Apotex, we are committed to delivering access to medicines and health products, and unlocking new possibilities for patients through partnerships. We are pleased to bring access to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) to the Mexican market upon regulatory approval. Our agreement with Formosa Pharmaceuticals further demonstrates Apotex's leading position as partner of choice in the Americas for pharmaceutical licensing and product acquisitions as we continue to execute our Journey of Heath growth strategy," said Alok Kanti, President, Apotex International.
"Having started our journey together in 2024, Formosa Pharma is pleased to expand the partnership with Apotex to include the Mexico territory," said Erick Co, President and CEO of Formosa Pharmaceuticals. "Our experience with Apotex's Canadian team underscored their commitment to branded and differentiated ophthalmology products, giving us full confidence that APP13007 will reach ophthalmologists and patients in Mexico as soon as possible."
About Apotex Inc.
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
40 minutes ago
- Forbes
What Are Smart Workcations? 5 Tips To Plan One This Summer
Find out why workcations are becoming more popular this year and how to take one that's balanced. Summer is just around the corner, and vacation plans are heating up. Many travelers are staying close to home this summer, staying in the U.S. or headed to Canada or Mexico, according to Squaremouth. Or they're staycationing at home, enjoying slow summer vacations. The tanking economy, jammed airports, travel disruptions, canceled flights and flight delays--plus lost luggage claims up 18%--are causing vacationers to rethink how they want to spend summer vacations. As a result, smart workcations are becoming more popular in the summer of 2025. Almost one year ago to the day I was writing about 'hushcations' for in which younger workers were sneaking vacations without calling off work or disclosing their location to their employers. The 'hush movement' grew among remote workers across the country as they tried to find risk-averse ploys to combine remote working with their desire for job flexibility. Now, as summer 2025 nears, Americans hit a 15-year low in travel planning, according to Fortune, explaining that job insecurity from DOGE layoffs and tariffs are shattering 2025 vacation plans. This summer vacationers are turning to a different kind of break called 'slow summer vacations,' shying away from baggage delays and loss, long lines, flight delays and disruptions and scaling back activities, cutting costs and allowing more unstructured time. A new Monster study reveals that most employees aren't getting the flexibility or support they need to enjoy the summer months. A notable 84% of U.S. workers say they aren't offered any designated summer benefits. And64% say they struggle to maintain a healthy work-life balance during the summer, When it comes to managing seasonal schedule conflicts, 42% report feeling unsupported by their managers or employers Among employees who receive summer benefits, 55% say it improves their productivity, proving that seasonal flexibility is more than just a perk--it's a performance booster. Workations are having a moment, as almost half of office workers (46%) have taken a one, with one in four doing so to obtain a better quality of life, and eight in ten claiming that a workation helps them cope with burnout. In fact, one in three workers have completed tasks on a beach or on a plane, according to a recent survey by Headway app. If you're like most people, the availability of technology and remote work make it impractical to plan a vacation totally devoid of work. White-knuckling through wondering if a work problem is going unaddressed actually raises your anxiety. Instead of planning a "cold turkey' vacation, it makes more sense to shoot for a smart workcation that balances play with work. Here are my five tips on how to have a fun and productive smart workcation: Limited communication with the office while vacationing can be less stressful than no communication at all and worrying about things piling up. Feeling that you're getting behind can make you feel out of control and make it harder to chill. Strictly enforced limits on vacations such as an hour a day to check email or make phone calls can help you relax. The breakneck speed of technology can activate your stress response, provoking a cortisol/dopamine squirt. Then you respond to the immediacy of the device as if it were a threat to extinguish. Be master instead of slave to your devices. Use custom ring tones for your family, friends or coworkers when you want to screen calls during off-hours. Ease up on instant messaging so you don't create the expectation that you're available 24/7. Avoid working right up until the moment you leave and head back to work right off the vacation. If possible, schedule an extra-day cushion before you depart and another when you return to ease back in. On vacation, alternate your time between staying active and restorative rest. A walk on the beach combined with five minutes of meditation both give you a biochemical boost. Activity raises endorphins. Quieting your mind stimulates the part of your brain that dampens the surges of adrenaline and cortisol accompanying stress. Choose a colleague you trust to manage day-to-day tasks during your absence, and make sure your coworkers know you'll be away. Designate a point person to be contacted on your voicemail and out-of-office email only on matters you want to be bothered about. Avery Morgan, workplace productivity expert and CHRO at Edubirdie, shares four easy-to-follow tips to help you stay focused, creative and one step ahead, without sacrificing the whole 'workation' vibe. "Your golden window of uninterrupted time, without Slack texts, emails and Whatnot, is while everyone else is sleeping, scrolling or sightseeing," Morgan explains. "Early mornings and late nights are your most productive window. No pings, no loud Zoom calls or zero distractions. Just you, your work and your full focus." "Besides, depending on your time zone vs. your team's, you might be able to sneak in deep work while everyone else is unavailable," she adds. 'So swap that midday hustle for some quiet early morning sessions--or whatever non-peak groove works.' "Travel time doesn't have to be downtime," Morgan says. "In fact, being on flights, trains and ferries is a perfect excuse to disconnect from meetings and dig into some much-needed big thinking." "No Wi-Fi? That can actually work in your favor!" she suggests. 'Jot down ideas, brainstorm projects, map out your goals--whatever your brain's been too busy to do lately. Pro tip: keep a tiny notebook or your Notes app handy. You'd be surprised how many good ideas hit when you're 30,000 feet in the air with no distractions in sight.' "Nothing disrupts your flow faster than bad Wi-Fi or a forgotten charger," Morgan warns. "Before you head out, test your hotspot, download offline backups of key files and make sure you've got your gear--adapters, headphones, chargers the works." "Scouting work-friendly spots at your destination is yet another way to streamline your processes," she advises. 'Know where the solid Wi-Fi is, have a backup location and steer clear of being the one scrambling for a charger in a noisy café with no signal.' "It's easy to blur the lines on a working trip," Morgan points out. 'If you don't set boundaries, work will bleed into your personal time and suck the joy out of your trip." She recommends blocking out active hours and downtime as well. "In your scheduled 'unplug' time, go sightseeing, take a nap or relax--just make sure when you're done for the day, you're really done. Protect your rest time like your productivity depends on it, because it really does." The beauty of smart workcations is that you gift yourself the freedom and to not just relax and play, but to do both. 'Try switching it up," Morgan says. "A cozy café in the morning, co-working space in the afternoon and beachside brainstorming in the evening. Different environments bring different vibes, and fresh vibes bring fresh energy.'
Medscape
an hour ago
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to
Yahoo
2 hours ago
- Yahoo
US-Mexico steel imports, Palantir stock, DoorDash & Symbiosys
Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including steel manufacturer Cleveland-Cliffs' (CLF) stock response to reports of US-Mexico trade talks, Palantir Technologies' (PLTR) move higher to a record intraday high, and DoorDash (DASH) acquiring advertising technology platform Symbiosys. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo! Finance's Market Minute. Stocks looking for momentum here as investors digest softer than expected inflation data. Shares of steel manufacturer Cleveland-Cliffs sliding as the U.S. and Mexico may be nearing a deal. The two nations reportedly close to an agreement that would remove President Trump's 50% tariffs on steel imports up to a certain volume. That's according to Bloomberg. Palantir on the rise as shares eye a record high close. That stock already hitting record intraday highs as Mizuho lifts its price target on that name from 94 to 116. The firm citing Palantir's, quote, stronger momentum in net new commercial logos. And DoorDash announcing its acquisition of ad tech platform Symbiosis. The food delivery company looking to expand its off-site advertising capabilities. DoorDash also introducing a new suite of AI-powered tools. And that's your Yahoo! Finance Market Minute. For more on what's trending on Yahoo! Finance, scan the QR code below to track the best and worst performing stocks. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
